Kenvue Inc. $KVUE Shares Sold by Korea Investment CORP

Korea Investment CORP lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 16.0% during the second quarter, HoldingsChannel reports. The firm owned 1,054,166 shares of the company’s stock after selling 200,633 shares during the period. Korea Investment CORP’s holdings in Kenvue were worth $22,064,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Vestcor Inc increased its stake in Kenvue by 13.6% during the 1st quarter. Vestcor Inc now owns 37,754 shares of the company’s stock worth $905,000 after buying an additional 4,529 shares during the period. Arkadios Wealth Advisors acquired a new stake in shares of Kenvue during the first quarter valued at about $442,000. US Bancorp DE increased its position in shares of Kenvue by 30.2% during the first quarter. US Bancorp DE now owns 359,597 shares of the company’s stock worth $8,623,000 after acquiring an additional 83,463 shares during the last quarter. TIAA Trust National Association acquired a new position in shares of Kenvue in the first quarter worth about $214,000. Finally, IFG Advisory LLC boosted its holdings in Kenvue by 19.4% in the first quarter. IFG Advisory LLC now owns 12,913 shares of the company’s stock valued at $310,000 after purchasing an additional 2,100 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KVUE shares. Redburn Partners set a $22.00 price objective on Kenvue in a report on Friday, September 26th. Jefferies Financial Group dropped their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a report on Friday, October 24th. The Goldman Sachs Group decreased their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, October 2nd. Finally, Edward Jones downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Price Performance

Shares of NYSE KVUE opened at $17.31 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The firm has a market capitalization of $33.15 billion, a PE ratio of 23.07 and a beta of 0.71. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The business’s fifty day moving average price is $16.06 and its two-hundred day moving average price is $19.56.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The company’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a $0.2075 dividend. The ex-dividend date was Wednesday, November 12th. This represents a $0.83 annualized dividend and a yield of 4.8%. Kenvue’s dividend payout ratio is 110.67%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.